Stephane Mouchabac
Overview
Explore the profile of Stephane Mouchabac including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
340
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bottemanne H, Berkovitch L, Gauld C, Balcerac A, Schmidt L, Mouchabac S, et al.
Neurosci Biobehav Rev
. 2023 Oct;
154:105410.
PMID: 37793581
For the past decade, ketamine, an N-methyl-D-aspartate receptor (NMDAr) antagonist, has been considered a promising treatment for major depressive disorder (MDD). Unlike the delayed effect of monoaminergic treatment, ketamine may...
12.
Oudin A, Maatoug R, Bourla A, Ferreri F, Bonnot O, Millet B, et al.
J Med Internet Res
. 2023 Oct;
25:e44502.
PMID: 37792430
The term "digital phenotype" refers to the digital footprint left by patient-environment interactions. It has potential for both research and clinical applications but challenges our conception of health care by...
13.
Millet B, Mouchabac S, Robert G, Maatoug R, Dondaine T, Ferreri F, et al.
Brain Sci
. 2023 Sep;
13(9).
PMID: 37759933
The current literature review aimed to evaluate the effectiveness of rTMS on the precuneus as a potential treatment for Alzheimer's disease (AD). Although the number of studies specifically targeting the...
14.
Ferreri F, Mouchabac S, Sylvestre V, Millet B, El Hage W, Adrien V, et al.
Brain Sci
. 2023 Sep;
13(9).
PMID: 37759875
The use of high-frequency Transcranial Magnetic Stimulation (HF-rTMS) of the right dorsolateral prefrontal cortex (DLPFC) in treating Post-traumatic Stress Disorder (PTSD) is currently regarded as a level B intervention (probable...
15.
Bourla A, Mouchabac S, Lorimy L, Crette B, Millet B, Ferreri F
Brain Sci
. 2023 Sep;
13(9).
PMID: 37759847
The measurement of the motor threshold (MT) is an important element in determining stimulation intensity during Transcranial Magnetic Stimulation treatment (rTMS). The current recommendations propose its realization at least once...
16.
Adrien V, Liewig J, Diot T, Ferreri F, Mouchabac S, Dubertret C, et al.
Front Psychiatry
. 2023 Jul;
14:1177311.
PMID: 37415693
Background: Psychotic transition (PT) is a crucial stage in schizophrenia. The Comprehensive Assessment of At-Risk Mental States (CAARMS) scale can be used to identify individuals at ultra-high risk (UHR) for...
17.
Carle-Toulemonde G, Goutte J, Do-Quang-Cantagrel N, Mouchabac S, Joly C, Garcin B
Encephale
. 2023 Jul;
49(4S):S24-S32.
PMID: 37414721
Introduction: The importance to assess and include the frequent comorbidities in the personalised care management plan of patients with functional neurological disorders (FND) has arisen through the years. FND patients...
18.
Carle-Toulemonde G, Hingray C, Alaoui O, Aybek S, Mouchabac S, Garcin B
Encephale
. 2023 Jul;
49(4S):S49-S55.
PMID: 37400336
After more than twenty years of academic research on functional neurological disorders (FND) throughout the world, a standardized care management strategy has emerged to allow a more adapted care offer...
19.
Mouchabac S, Lacambre M, Carle-Toulemonde G, Drapier D
Encephale
. 2023 Jul;
49(4S):S42-S48.
PMID: 37400335
Functional neurological disorders (FND) have long been a challenge for medicine, both on clinical and psychodynamic point of view. The medico-legal issue is often relegated to the background in medicine,...
20.
Conejero I, Thouvenot E, Hingray C, Hubsch C, El-Hage W, Carle-Toulemonde G, et al.
Encephale
. 2023 Jul;
49(4S):S18-S23.
PMID: 37394415
Objectives: Functional neurological disorders have witnessed intense research activity in the fields of structural and functional neuroimaging for more than twenty years. Thus, we propose a synthesis of recent research...